AMG 221 / Amgen - LARVOL DELTA

Embracing metabolites in drug discovery - Identification, synthesis, and characterization of the metabolites observed for AMG 221, a clinical candidate for type II diabetes that inhibits the enzyme 11beta-hydroxysteroid dehydrogenase type 1. (ACS-Fall 2024) - "In this presentation, we will review how these metabolites were identified, synthesized, and characterized, and show that certain metabolites had potency similar to and with improved pharmacokinetic properties compared to AMG 221. We will then discuss how these results influenced our strategy as we moved forward into the clinic with AMG 221."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus